Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM?

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The New England Journal of Medicine. The CONNECT study focused on adults with Type 2 diabetes who are not using insulin and assessed clinical outcomes with standalone real time CGM. Researchers reported significant clinical benefits in glycemic control for this group when using DexCom's G7 continuous glucose monitoring system. The NEJM publication of the CONNECT trial for...